Boston, Mass.– Adams Clinical, a leading neuroscience-focused clinical trial site network, has announced the promotion of Dr. Stephanie Rutrick to Chief Medical Officer. Dr. Rutrick, a fellowship-trained vascular neurologist, joined Adams Clinical in 2022 to focus on clinical research and collaborate with pharmaceutical companies in the development of next-generation Alzheimer’s disease treatments as a Neurology Principal Investigator.
In her new role, Dr. Rutrick will oversee medical safety strategy across Adams Clinical’s locations, which include Watertown, MA; Boston, MA; Harlem, NY; Bronx, NY; Dallas, TX; and a newly planned site in Philadelphia, PA, set to open in Spring 2025. She will also continue supporting trials as a Neurology Principal Investigator at the Watertown location.
“Adams is uncompromising with the safety of the participants who place their trust in us when joining a clinical trial,” said Chris Reef, CEO of Adams Clinical. “Dr. Rutrick’s experience and leadership will ensure that our medical safety processes are optimized and consistent across all our locations. We make data-driven decisions and apply evidence-based best practices to deliver on our commitment to sponsors to execute their trials safely and with integrity to generate consistent, high-quality data.”
Dr. Rutrick, reflecting on her new role, shared a personal connection to her work. “When my grandmother was deteriorating from presumed Alzheimer’s disease, my family grappled with the same questions that I hear every day from trial participants—their loved ones and treating physicians were considering participation in a clinical trial of a potentially life-changing medicine,” she said. “It is my goal to ensure that we continue to evolve in lockstep with the clinical development landscape. Adams Clinical is positioned to be the leading site network for the delivery of trials testing GLP-1 agonists in psychiatric indications, including substance use disorders. We are taking proactive steps to support the most cutting-edge science in studies of psychedelic medicines, the next generation of disease-modifying treatments for Alzheimer’s disease, and other novel drug classes entering neuroscience clinical trials.”
Dr. Rutrick and other members of the Adams Clinical leadership team will be attending the AD/PD International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Vienna, Austria, this week. A poster co-authored by Dr. Rutrick will be presented by Roche Diagnostics at the congress.
With Dr. Rutrick’s promotion, Adams Clinical reinforces its commitment to advancing neuroscience research and maintaining the highest safety standards in clinical trials.
